Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
– Results demonstrate melanocortin agonists may represent a new therapeuticavenue to treat diabetic nephropathy – Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J., May 30, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the …